Expression And Its Significance Of Cyclin-dependent Kinases 16 Gene In Serous Ovarian Cancer Cells

Objective: To explore the expression of the cyclin-dependent kinases16(CDK16) gene in ovarian cancer cells and its pathological role in proliferation and migration of ovarian cancer cells. Methods: the m RNA level of CDK16 in ovarian cancer cell lines(SK-OV-3, OVCAR-3 and HO-8910) and in ovarian cancer tissues were measured by q RT- polymerase chain reaction(PCR)and the protein level of CDK16 in ovarian cancer tissue was detected by immunohistochemical staining and Western blot, respectively. CDK16 RNAi was constructed into a lentivirus vector, which was then used to infect SK-OV-3 cells.Proliferation of SK-OV-3 cells was detected by MTT assay and colony formation assay, whereas cell cycle profile and apoptosis were analyzed by flow cytometer.Cell migration and athletic ability was determined by wound healing and transwell assays. Results: Compared with normal cells 293 T, CDK16 m RNA expression in ovarian serous carcinoma cell line SK-OV-3, OVCAR-3 and HO-8910 were 7.04 ±1.26, 7.52 ± 1.91 and 5.62 ± 0.10, respectively. CDK16 m RNA in 3 strains of ovarian serous cell were significantly higher than in normal cells(P < 0.01). The expression of CDK16 at m RNA and protein levels in non-neoplastic ovarian tissue were 46.08 ± 10.05 and43.66 ± 8.01, respectively. Meanwhile, the expression of CDK16 at m RNA and protein levels in serous ovarian cancer were 146.73±11.02 and 185.61±23.08. CDK16 m RNA and protein levels in serous ovarian cancer were significantly higher than in non-neoplastic ovarian tissue(P <0.01). CDK16 m RNA in the pathological stage I, II, III, IV of serous ovarian cancer were 123.20±9.42, 163±21.37, 129.40±8.79 and 167.96±18.21 while CDK16 protein in the pathological stage I, II, III, IV of serous ovarian cancer were 152.27±11.70, 201.43±21.31,153.51±6.59 and 217.20±9.72, respectively. Interestingly, CDK16 m RNA and protein levels were higher in later stage of serous ovarian cancer than in earlier stage of serous ovarian cancer. The expression of CDK16 at m RNA and protein levels in different pathological grades(G1,G2 and G3) of serous ovarian cancer were 125.93±7.30, 129.73±14.91,148.29±9.50, 197.49±18.30,152.03±6.13 and 212.03±21.30, respectively. CDK16 m RNA and protein levels were higher in lower grade of serous ovarian cancer than in higher grade of serous ovarian cancer. The SK-OV-3 cells infected with a CDK16-RNAi containing lentivirus showed significantly decreased proliferation at the fifth day after infection(P< 0.05). The infected SK-OV-3 cells showed an increased G1 fraction of the cell cycle, increased apoptosis, decreased migration ability, as well as decreased ability to form colonies in soft agar(P< 0.05). Conclusion: CDK16 is highly expressed in ovarian cancer cells while silencing CDK16 can not only significantly inhibit cell proliferation and migration but also promote cell apoptosis. This study provides experimental data for further investigate the possible pathological role of CDK16 gene in the pathogenesis of ovarian cancer.